Navigation Links
ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion)

the scientific literature or conclusions regarding safety or effectiveness made by the FDA in the approval of other drugs. This regulatory pathway potentially makes it easier for drug manufacturers to obtain rapid approval of new forms of drugs based on the FDA's approval of the original drug. Some examples of products that may be allowed to follow a 505(b)(2) path to approval are drugs that have a new dosage form, strength, route of administration, formulation or indication. Upon approval, a drug may be marketed only for the FDA-approved indications in the approved dosage forms. Further clinical trials are necessary to gain approval for the use of the product for any additional indications or dosage forms.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. The Company seeks to improve the performance and safety of existing treatments by addressing significant problems such as drug metabolism, bioavailability, excessive toxicity and treatment resistance. More information can be found on the Company's web site at http://www.adventrx.com.

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors that, if they do not materialize or prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that preclinical and clinical results are not indicative of the success of subsequent clinical trials and that products will not perform as preclinical and clinical data suggests or
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX to Present CoFactor Multiagent Therapy Data at AACR Annual Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:5/5/2015)... BEACH, Calif. and ST. LOUIS ... diabetes, high blood pressure or high cholesterol may achieve ... of performance-based networks, according to early results of a ... Scripts (NASDAQ: ESRX ). "Pharmacists are ... and their frequent interactions with our members presents enormous ...
(Date:5/5/2015)... , May 5, 2015 Big Market Research ... US, Europe , ( France , ... Spain , UK) and Japan . ... reviewed. The report provides the 5-year test volume and sales forecasts ... NAT, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, and ...
(Date:5/5/2015)... YORK , May 5, 2015 ... ("E-QURE" or the "Company"), a premier provider of innovative ... treatment, today issued an update to shareholders and the ... the financing and acquisition of the proprietary Bioelectrical Signal ... the completion of its S-1, as well as its ...
Breaking Medicine Technology:SCAN Health Plan, Express Scripts' Quality Network Improves Medicare Beneficiary Health 2SCAN Health Plan, Express Scripts' Quality Network Improves Medicare Beneficiary Health 3SCAN Health Plan, Express Scripts' Quality Network Improves Medicare Beneficiary Health 42015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 22015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 3E-QURE Corp. Issues 2014 - 2015 Update to Shareholders 2E-QURE Corp. Issues 2014 - 2015 Update to Shareholders 3E-QURE Corp. Issues 2014 - 2015 Update to Shareholders 4E-QURE Corp. Issues 2014 - 2015 Update to Shareholders 5
(Date:5/5/2015)... May 05, 2015 AxoGen, Inc. ... on the $1.6 billion peripheral nerve repair market, reported ... ended March 31, 2015 compared to $3.14 million in ... adoption of our proprietary portfolio of nerve repair products ... AxoGuard® Nerve Protector – and our solid sales execution ...
(Date:5/5/2015)... 2015 The global lab automation market ... $3,474.2 Million in 2014, at an estimated CAGR of ... lab automation market on the basis of equipment and ... On the basis of application, Lab Automation Market is ... proteomics solutions. Drug discovery is a major application of ...
(Date:5/5/2015)... Viverae®, a health management and ... leading multinational developer, manufacturer and marketer of innovative, ... urology, oncology and surgical specialty products, as the ... Vanguard Award recognizes outstanding achievement in the design ... significant client base. , Viverae reviewed the employee ...
(Date:5/5/2015)... 2015 Dr. Patricia George knows all ... A pulmonologist and pulmonary hypertension specialist at the University ... work event when an initial idea entered her mind ... in the audience at the 2010 PHA International Conference,” ... providers – were recalling their climb up Mt. Kilimanjaro ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 In a April ... The Herald-Times , the Missouri State Highway Patrol (MSHP) ... Methamphetamine production or use for the second year in a ... to the FBI, reported 1,469 incidents in 2014 alone, around ... only around 2% of the US Population calls Indiana home, ...
Breaking Medicine News(10 mins):Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 4Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 2Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 3Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 4Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 5Health News:Viverae® Honors C. R. Bard, Inc. with 2015 Vanguard Award 2Health News:World PH Day: Team PHenomenal Hope Races to Spread the Word about Pulmonary Hypertension 2Health News:A Forever Recovery Releases New Information on the Epidemic Rise Of Methamphetamine Abuse in Midwest America 2
... examines the use of tissue-engineered scaffolding made of cartilage cells, ... defective cartilage tissue. ,Cartilage cells are extracted ... body, where new cartilage tissue is grown along the structure. ... ,The procedure was extremely successful in tested mice as the ...
... between the immune systems of humans and opossums, the ... lead to breakthroughs in the understanding and treatment of ... found only in the Australian island state of Tasmania. ... full set of genetic information of the South American ...
... as to why oral cancer has been on the rise ... candidates . American scientists say that oral sex is a ... HPV between partners and may give cause to oral cancer ... any substance known to predispose to the disease. ...
... A new study reveals that almost two-thirds of ... their life, but very few of them experience ... certain emotional resilience in children, but it also suggests ... from adults, said William Copeland of Duke University Medical ...
... A new vaccine aimed at preventing cervical cancer is nearly ... papillomavirus (HPV) responsible for most cases of cervical cancer. ... published in the May 10 issue of the New England ... of young women, a series of three shots of a ...
... Research Hospital had a molecules eye view of the ... a double-strand break to link together the broken ... the twisted, ladder-like structure of DNA, breaking it into ... for this project, the St. Jude researchers could determine ...
Cached Medicine News:Health News:Treatment of Premature Babies, Opossums Could Help 2Health News:Swallowing The Bitter Pill-Oral Sex Linked To Oral Cancer 2Health News:Two-thirds of US Children Experience Trauma, but Recover Fast 2Health News:Study Shows Continued Success for New HPV Vaccine Against Virus 2Health News:DNA Repair Proteins Monitored at Double-strand Break 2
Its generous filter placement, MicroPoint design, and reference marks at 10, 50, and 100 ul make this ART tip ideal for many 200 ul pipettors....
This extra long 180 ul pipet tip will reach the bottom of large tubes and vials, preventing your pipettor from contacting the sample container....
Diamond Filter Tips play a critical role in preventing aerosol-borne contamination. Also available sterilized (no need to autoclave) and certified free of detectable RNase, DNase, DNA, RNA, and prote...
This tip's tight fit and MicroPoint design make it ideal for use with the Pipetman P-20. 10 L reference mark ensures consistent pipetting with low volumes....
Medicine Products: